PMID- 23844829
OWN - NLM
STAT- MEDLINE
DCOM- 20140730
LR  - 20181202
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 19
IP  - 8 Suppl
DP  - 2013 Jun
TI  - Current state of type 2 diabetes management.
PG  - S136-42
AB  - Type 2 diabetes mellitus (T2DM) and its associated comorbidities are a major 
      public health issue in the United States. Although a sizable pharmacotherapeutic 
      armamentarium exists to combat this disease and several sources have published 
      evidence-based management guidelines, the management of patients with T2DM 
      remains complex and suboptimal. Currently available medications target various 
      organs in an attempt to normalize hyperglycemia; however, newer agents targeting 
      additional organ systems are in development. Among these, a class of medications 
      that inhibit the sodium glucose cotransporter 2 (SGLT2) in the kidney show 
      promise in their ability to decrease glucose reabsorption and increase glucose 
      excretion. In particular, one of these compounds, canagliflozin, recently was 
      approved by the US Food and Drug Administration. Despite such advances, the 
      natural course of T2DM often eventually leads to the initiation of insulin 
      therapy. A working knowledge of management guidelines, particularly concerning 
      when and how to initiate monotherapies, combination therapies, and complex 
      insulin regimens, is essential for optimal patient management. Insulin therapies 
      should mimic normal physiologic levels of insulin through the use of both basal 
      and bolus insulin analogues. Recognition of the various factors influencing 
      therapeutic choices is also critical for improved patient management.
FAU - Molitch, Mark E
AU  - Molitch ME
AD  - Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern 
      University Feinberg School of Medicine, Chicago, IL, USA. 
      molitch@northwestern.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (A1CF protein, human)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Guideline Adherence
MH  - Health Care Surveys
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/therapeutic use
MH  - Insulin Resistance/physiology
MH  - Practice Guidelines as Topic
MH  - RNA-Binding Proteins/blood
MH  - Sodium-Glucose Transporter 2 Inhibitors
MH  - United States
EDAT- 2013/07/16 06:00
MHDA- 2014/07/31 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/16 06:00 [pubmed]
PHST- 2014/07/31 06:00 [medline]
AID - 85123 [pii]
PST - ppublish
SO  - Am J Manag Care. 2013 Jun;19(8 Suppl):S136-42.